Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Head and Neck Squamous Cell Carcinoma (HNSCC): Update Bulletin #3 [December 2018]

Product Code:
596200998
Publication Date:
December 2018
Format:
PDF
Price:
$1,315

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the head and neck squamous cell carcinoma (HNSCC) market. KOLs provide their candid insights on key events, including: Merck & Co.’s presentation of positive data from the Phase III Keynote-048 trial of Keytruda (pembrolizumab) monotherapy in the first-line treatment of recurrent or metastatic HNSCC; positive data released from the Keynote-048 trial for Keytruda in combination with platinum (cisplatin or carboplatin) and 5-FU versus EXTREME, for the first-line treatment of recurrent or metastatic HNSCC; and the presentation of data from the Phase Ib/II SCORES trial of AZD9150, AstraZeneca’s antisense therapy targeting STAT3 (also called danvatirsen), in combination with durvalumab (Imfinzi; AstraZeneca) in recurrent or metastatic HNSCC.

Business Questions:

• How do KOLs view the data from the Keynote-048 trial for Keytruda monotherapy in the first-line treatment of recurrent or metastatic HNSCC?
• How are the Keynote-048 data perceived in terms of magnitude of benefit and tolerability for Keytruda monotherapy?
• In which patients and to what extent is Keytruda monotherapy likely to be used in the first-line treatment of recurrent or metastatic HNSCC?
• How do KOLs view the Keynote-048 data for Keytruda in combination with chemotherapy?
• Will the efficacy of Keytruda in combination with chemotherapy justify the toxicity burden?
• How do KOLs view the future of Keytruda in combination with chemotherapy in the first-line treatment of recurrent or metastatic HNSCC?
• How do KOLs view the findings from the Phase Ib/II SCORES trial of AZD9150, in combination with durvalumab, in recurrent or metastatic HNSCC?
• Is there a convincing rationale for targeting STAT3 in head and neck cancer treatment?
• In which patients or settings could AZD9150 plus durvalumab be most effectively positioned?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved